Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

Bill Number

H.Res. 803

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-10-10: Referred to the House Committee on Energy and Commerce.

Last Updated

2025-12-15T16:47:46Z

AI-Generated Summary

Purpose of the Legislation

This House Resolution (H. Res. 803) expresses the House of Representatives' urging to the Director of the Food and Drug Administration (FDA) to reassess the safety of chemical abortion drugs (medications used to end pregnancies, such as mifepristone). It highlights concerns from recent independent studies about higher complication rates and calls for a public safety review. The resolution is non-binding, meaning it does not create new laws but serves as a formal statement of position.

Key Provisions Outlined

• Background Concerns (Whereas Clauses): The resolution cites expansions in access to chemical abortion drugs under the Obama and Biden administrations, including removing requirements for in-person visits, reporting of serious side effects, follow-up care, and allowing mail distribution. It notes that these changes raise issues like potential legal violations, risks of coercion or abuse, misuse leading to harm, the prevalence of chemical abortions (over half of U.S. abortions), taxpayer funding of providers, a recent FDA approval of a generic mifepristone version on September 30, 2025, and independent research showing complication rates 22 times higher than FDA reports.
• Core Urging (Resolved Clause):
• Reevaluate the safety of all chemical abortion drugs based on recent independent studies.
• Publicly release a comprehensive safety review that includes real-world outcomes and complications.

Significant Changes to Existing Law Introduced

This resolution introduces no changes to existing law, as it is a concurrent resolution of the House and lacks the force of law. It does not amend statutes, regulations, or FDA policies but aims to influence agency actions through political pressure.

Potential Impacts

• On Government Agencies: May prompt the FDA to conduct or accelerate safety reviews, potentially leading to revised guidelines, labeling, or restrictions on chemical abortion drugs. It could also affect how taxpayer funds are allocated to providers.
• On Citizens: Women and girls using these drugs might face altered access or increased scrutiny if reviews lead to tighter regulations, potentially raising safety awareness but also complicating healthcare options. The resolution expresses concerns about physical, emotional, and coercive harms.
• On International Relations: No direct impacts mentioned, though broader U.S. abortion policy shifts could influence global health discussions or aid programs related to reproductive rights.
• Broader Effects: Could contribute to more abortions via expanded access (per the resolution's concerns) or undermine state-level pro-life laws by increasing drug availability.

Main Stakeholders Affected

• FDA and Healthcare Regulators: Directly urged to act, facing potential pressure for transparency and reevaluation.
• Women and Girls Seeking Abortions: Primary users of chemical abortion drugs, potentially impacted by safety changes or access restrictions.
• Abortion Providers and Manufacturers: Taxpayer-funded entities prescribing or producing these drugs, subject to ethical, legal, and funding scrutiny.
• Pro-Life Advocates and State Governments: Supporters of the resolution, who may see it as supporting efforts to limit abortions and enforce state laws.
• Taxpayers: Indirectly affected through funding of providers and potential shifts in public health spending.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: Highlights potential federal law violations from access expansions and recent FDA approvals; could fuel lawsuits challenging drug approvals or distribution methods, especially post-Dobbs v. Jackson (2022 Supreme Court decision overturning federal abortion rights).
• Constitutional Implications: Touches on tensions between federal regulatory authority (FDA oversight) and state powers over abortion, as well as reproductive privacy rights under the 14th Amendment; no direct constitutional challenges raised, but it underscores debates on bodily autonomy versus fetal protection.
• Political Implications: Reflects partisan divides on abortion, introduced by Republican representatives amid ongoing national debates; as a House-only measure, it signals congressional intent but requires broader support for enforcement, potentially influencing future legislation or executive actions.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Rose, John W. [R-TN-6]

Cosponsors (11)

Rep. Harshbarger, Diana [R-TN-1], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. LaMalfa, Doug [R-CA-1], Rep. Biggs, Sheri [R-SC-3], Rep. Moore, Barry [R-AL-1], Rep. Hageman, Harriet M. [R-WY-At Large], Rep. Grothman, Glenn [R-WI-6], Rep. Aderholt, Robert B. [R-AL-4], Rep. Harris, Andy [R-MD-1], Rep. Guest, Michael [R-MS-3], Rep. Cline, Ben [R-VA-6]

Recent Actions

• 2025-10-10: Referred to the House Committee on Energy and Commerce.
• 2025-10-10: Submitted in House
• 2025-10-10: Submitted in House

Bill Versions

• Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes. — issued 2025-10-10 — PDF (3 pages)